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REGIONAL ANALYSIS OF CANDIDATE GENES ASSOCIATED WITH
ACUTE GVHD FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANTATION
Chien, J.W.1,3, Zhang, X.C.2, Fan, W.H.2, Wang, H.2, Zhao, L.P.2,
Martin, P.J.1,3, Storer, B.E.1, Boeckh, M.1,3, Warren, E.H.1,3,
Hansen, J.A.1,3 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2Fred Hutchinson Cancer Research Center, Seattle, WA; 3Univer-
sity of Washington School of Medicine, Seattle, WA
Background: Many non-MHC genetic variants that influence the
risk and severity of acute graft versus host disease (GVHD) and other
adverse transplant outcomes have been identified. However, the ge-
netic regions surrounding these candidate variants have not been
evaluated in detail to confirm the region of highest association and
identify targets for functional studies.
Methods:We evaluated candidate genes previously reported to be as-
sociatedwith acuteGVHDandused genomewide data generated using
the Affymetrix GeneChipGenome-Wide Human Single Nucleotide
Polymorphism (SNP) Array 5.0 from a cohort of 1,560 donor-recipient
pairs who had allogeneic hematopoietic cell transplantation between
1992 and 2005. Actual and imputed SNP genotypes within and1/-50k
base pair surrounding each genewere evaluated. A permutationmethod
was used to establish gene-wide statistical significance, accommodating
multiple comparisons of SNPs within and surrounding each gene.
Results: 40 publications between 1998 to 2009 reported associations
between acute GVHD and 34 genetic variants in 24 genes: CCR5,
CD31, CTLA4, ESa, FAS, FcgRIIIb, HSP70-hom, IFNg, IL10,
IL10Rb, IL1a, IL1b, IL1Ra, IL2, IL23R, IL6,MADCAM1,MTHFR,
NOD2, TGFb1, TNF, TNFRII, VDR, VEGFa. Fifteen of the 34
originally reported SNPs were successfully imputed or included on
the 5.0 array. Among these 15, we reproduced the association of
rs2075800 in HSPA1L with grade III-IV acute GVHD (p5 0.0035),
but were not able to confirm the association between SNPs and
GVHD. The SNPs that were most significantly associated with
GVHD were rarely in the same location as the original candidate
SNP. In adjusted analyses, four (CTLA4, IL6, MADCAM1, and
TNFRII)wereassociatedwithgrade II-IVacuteGVHD(p-value range
0.0017-0.0085), eight were associated with grade III-IV acute GVHD
(CCR5, HSPA1L, IFNG, IL10RB, MADCAM1, NOD2/CARD15,
TNF, and VEGFa; p-value range 0.0005-0.007), six (IL10, IL23R,
NOD2/CARD15 and VDR) were associated with transplant-related
mortality (p-value range \ 00001-0.0017), and six (FAS, IL10,
IL23R, MADCAM1, NOD2/CARD15 and TGFB1) were associated
with all cause mortality (p-value range\0.0001-0.0051).
Conclusions: These results illustrate a high-resolution approach
utilizing genome wide data for fine-mapping genetic associations
identified through candidate studies and may provide important in-
formation for guiding the selection of candidates for functional stud-
ies and biomarker clinical trials.
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IN VIVO T CELL DEPLETION WITH DEXAMETHASONE REDUCES GRAFT
VERSUS HOST DISEASE (GVHD) WITH MINIMAL SIDE EFFECTS AND NO
ADDITIONAL RISK OF EARLY RELAPSE AFTER ALLOGENEIC PERIPHERAL
BLOOD STEM CELL (PBSC) TRANSPLANTATION
Innis-Shelton, R.D., Ashraff, K., Li, Y., Mehta, N., Salzman, D.E.,
Tilden, A., Vaughan,W.P., Lamb, L. University of Alabama at Birming-
ham, Birmingham, AL
Cytokine mobilized stem cells collected from peripheral blood are
routinely used for allogeneic hematopoietic stem cell transplantation
(alloHSCT). Advantages to PBSCuse include better donor tolerance
and more rapid engraftment than marrow source stem cells. Disad-
vantages of PBSC include the increased incidence and severity of
chronic GVHD due to higher numbers of alloreactive T cells.1.2
Objective: We hypothesized that a short course of dexamethasone
(Dex) given to donors prior to PBSC collection would reduce the
T cell content of the graft resulting in decreased incidence and sever-
ity of GVHD without compromise to engraftment, infection rate,
immune reconstitution or relapse rates.
Methods: At our institution, 122 consecutive patients treated with
alloHSCT for various malignancies between 1998-2007 received
PBSCs purged of T cells in vivo by oral administration of Dex(10mg/m2) to the donor on each of the last 3 days of G-CSF mobi-
lization. The median patient age was 48 (range 19-68), all were con-
ditioned with busulfan based regimens, 41 patients had low risk
ASBMT disease status vs 53 with high risk disease. All received
CSA1MTX GVH prophylaxis.
Results: An earlier report of the first 98 patients vs 29 controls mo-
bilized without Dex demonstrated a 2 log reduction in the
CD31graft content of the collected product, and a low incidence
and severity of acute GVHD(19% grade II - IV at 100 days). We
now report an updated retrospective multivariate analysis of the in-
cidence of acute and chronic GVHD, time to engraftment, relapse
rates, and 1 year overall survival of the entire cohort, with longer fol-
low up (min 5 1yr). Final analysis of all graft products contained
CD31 and CD341contents of 3.46x108(sd 5 2.32x108) and
7.85x106(sd5 5.02x106) cells/kg respectively vs. 1.09x1010 CD31(sd
2.19x1010) and 7.84x106 CD 341cells/kg (sd 5.34x106) in the 29 in-
stitutional controls. Patients in the G-Dex group experienced 26%
grade II-IV acute and 9.3% extensive chronic GVHD, uniform en-
graftment success, normal pattern immune reconstitution, and an
18% malignant disease relapse rate at 1 year.
Conclusion: A short course of Dex given to donors prior to PBSC
collection is a viable strategy for in vivo T cell depletion. Donors tol-
erated the steroid well, bone pain symptoms associated with GCSF
mobilization were ameliorated, and there were no untoward effects
of steroid use. Comparison of this patient population with 3:1
matched CIBMTR controls is approved and in progress.
11
CELLULAR ANTI-VIRAL IMMUNE RESPONSES ARE INCREASED IN THE
ABSENCE OF VASOACTIVE INTESTINAL PEPTIDE
Li, J.-M.1, Hossain, S.M.1, Wang, Y.1, Fan, K.1, Harris, W.1,
Waschek, J.2, Waller, E.K.1 1Winship Cancer Institute, Emory Univer-
sity, Atlanta, GA; 2University of California, Los Angeles, CA
Backgrounds: Previously we reported that mice ‘‘knocked-out’’ for
vasoactive intestinal peptide (VIP) had increased blood levels of anti-
viral T-cells following murine cytomegalovirus (mCMV) infection,
and that the absence of VIP in donor cells did not increase GvHD in
amurinemodel of allogeneic BMT. In this study, we usedVIP-knock-
out (KO)mice to further investigate the effects andmechanismsofVIP
onmurineanti-viral immune responses inperipheral lymphoidorgans.
Methods: VIP-KO mice and wild-type (WT) littermates were in-
fected with a sub-lethal dose of mCMV by intraperitoneal injection.
The mice were euthanized and the spleens and the livers sampled at
distinct time points. CD81 T-cell responses to virus were measured
by flow cytometry using mCMV peptide-MHC class I-tetramers.
Natural killer (NK) cell activity was tested by lysis of YAC-1 target
cells. Viral load was determined by plaque assay. Expressions of
CD25, CD62L, CD69, ICOS, killer cell lectin-like receptor G1
(KLRG1), PD-1,TNF-a, IFN-g, IL-4, and IL-10 in lymphocyte sub-
setswere examined by flow cytometrywith respective isotype controls.
Results: VIP-KOmice had faster and higher levels of antigen specific
anti-viralT-cells, enhancedNKcytolytic activity, and faster rateof viral
clearance after mCMV infection compared with WT mice. VIP-KO
CD41 T-cells transiently expressed higher levels of CD25 compared
with WT CD41 T-cells at 3 days after mCMV infection. VIP-KO
mice had equal levels of PD-1 for 10 days post infection compared
with WT mice. The levels of ICOS1 and KLRG11 activated CD81
T-cells were increased in mCMV-infected VIP-KO mice and their
levels correlated with the enhanced mCMV-peptide-MHC tetramer1
specific anti-viral responses in CD81 T-cells. IFN-g expression was
significantly higher in VIP-KO NK cells and in the subset of CD81
dendritic cells (DC), while TNF-a expression was higher in CD41
and CD81 T-cells from mCMV-infected VIP-KO mice compared
with WT controls. No significant differences were noted in the levels
of Th2 cytokine expression in lymphocytes between VIP-KO and
WT mice after mCMV infection. Taken together, these data suggest
that VIP expression by T-cells modulates DC and NK function and
suppresses Th1/Tc1 cellular anti-viral immune responses.
Conclusion: VIP negatively regulates T-cell and NK cell anti-viral
immune responses. The VIP pathway is an attractive target for phar-
macological intervention to enhance anti-viral activity of NK cells
and CD81 T-cells.
